The code block below illustrates how one might use # and // as comments in your logic and calculations.

This value you provided is not a number. Please try again.

This value you provided is not an integer. Please try again.

The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again.

The value you provided must be within the suggested range

The value you provided is outside the suggested range

This value is admissible, but you may wish to double check it.

The value entered must be a time value in the following format HH:MM within the range 00:00-23:59 (e.g., 04:32 or 23:19).

This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now.

This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now.

This field must be a valid email address (like joe@user.com). Please re-enter it now.

The value you provided could not be validated because it does not follow the expected format. Please try again.

Required format:

RFA 6 - Submission Portal

Sixth Call for Proposals: Evaluate Canadian Biotechnologies with Randomized Controlled Trials

Welcome to the ACT Canada submission portal for the sixth request for applications (RFA 6). Your application must be submitted via this portal, emailed applications will not be accepted.

Please complete all questions in this portal and upload a single PDF of your application. Naming convention for the PDF should include a NPI last name and project title (e.g., "Smith_ProjectTitle.pdf").

Application Components:

Please refer to the Call for Proposals (link updated) for detailed breakdown of section requirements and scoring.

Summary: 1 page
Written Proposal: 4 pages if written in English or 5 pages if written in French.
Budget and justification: 1 page
References, figures, or tables: 1 page (optional)
Deadline: Submit by Sunday, January 5, 2025 at 11:59pm ET
- Late submissions will not be accepted.
- Once submitted, confirmation of receipt will be provided. If you do not hear back within 24 hours, please follow up to ensure successful delivery.

If you have any concerns or questions about this application process, please contact the Coordinating Team at ACT.Canada@phri.ca by Friday, December 20th.

Thank you for your interest in the ACT Canada Consortium and for your application.

Please save progress as you go using the [Save & Return Later] button at the bottom of the form.

1. Which ACT Canada Research Network has endorsed this application?

Each ACT Network (link) can endorse a maximum of 3 applications
Networks should endorse proposals most relevant to their constituents, especially their patients.
No letter of support is required from the supporting ACT Network.

Select ACT Network

2. What is the trial name?

a) Acronym
b) Full Name

3. What is the trial structure?

a) Phase
b) Design (e.g. RCT)

Please save progress as you go using the [Save & Return Later] button at the bottom of the form.

4. How many Principal Investigators are included in this application?

PI(s) will have their substantive role in Canada for the duration of the project's term.
- their primary affiliation is in Canada; or
- they spend at least 50% of their time at the designated Canadian institution.
PI(s) must report their shareholding status in the company.
PI(s) can only submit one application to this competition.
Full membership details can be included in the PDF.

Select number of PIs
max 3

(select number of PIs)

4.1 Nominated Principal Investigator (PI1)

Name, Email, Biotech Shareholding Status, Institution, and Province are required

a) PI1 Name
b) PI1 Email
c) PI1 Biotech Shareholding Status
d) PI1 Institution
e) PI1 Province
f) PI1 Gender (optional) for demographics
g) PI1 Career Stage (optional) e.g., early career, independent, mid career, senior

4.2 Co - Principal Investigator (PI2)

Name, Email, Biotech Shareholding Status, Institution, and Province are required

a) PI2 Name
b) PI2 Email
c) PI2 Biotech Shareholding Status
d) PI2 Institution
e) PI2 Province
f) PI2 Gender (optional) for demographics
g) PI2 Career Stage (optional) e.g., early career, independent, mid career, senior

4.3 Co - Principal Investigator (PI3)

Name, Email, Biotech Shareholding Status, Institution, and Province are required

a) PI3 Name
b) PI3 Email
c) PI3 Biotech Shareholding Status
d) PI3 Institution
e) PI3 Province
f) PI3 Gender (optional) for demographics
g) PI3 Career Stage (optional) e.g., early career, independent, mid career, senior

5. Who is the Canadian Biotechnology Partner for this submission?

Canadian-Controlled Private Corporation (CCPC)
- CCPC is a private corporation incorporated in Canada that is not controlled by non-residents or public corporations, meaning non-Canadian residents cannot directly or indirectly control the company or own more than 50% of the company or of its voting power via the board.
Biotechnology, or biotech, is the intersection of biological, engineering and computer sciences.
- Examples of biotech include the following: drug (including natural health products), living organisms (or parts of them), biological systems

a) Company Name
b) Business Number
c) Product Type (e.g. drug, device, data system)
d) Canadian controlled?
e) Contact Name
f) Contact Email
g) Company Website (optional)

Please save progress as you go using the [Save & Return Later] button at the bottom of the form.

6. Which Data Coordinating Centre is supporting this trial?

a) Centre Name
b) Centre Location

7. Please provide timeline and budget details

a) End Date ACT funding must be used by June 30, 2026
b) Budget Request max $400,000 CAD
c) Institution Holding Funds
d) PDF includes the following statement:
"I have confirmed my institution (which will hold the grant funds) has reviewed my proposed budget and deems all items to be CIHR eligible."

Please save progress as you go using the [Save & Return Later] button at the bottom of the form.

8. Which email address should be used for correspondence and confirmation of submission?

Correspondence Email

9. PDF Checklist:

We provide this checklist for your convenience only.
It is your responsibility to ensure the PDF contains all requirements as described in the Call for Proposals (link updated) and to check each section for completion, accuracy, and eligibility.

Eligibility Criteria	Included in PDF?
a) Leadership: The nominated principal investigator must be a Canadian researcher who is a member of an ACT Network. Leadership must be in partnership with a biotech company representative.
b) PI applications: The nominated principal investigator(s) can only submit one application to this competition
c) Canadian Biotech: The trial must evaluate a biotechnology and the biotechnology company partner must be Canadian-controlled.
d) Trial Design: The proposal is an RCT and not a product validation or observational study.
e) ACT Network: The trial must be endorsed by one of the 34 ACT Networks.
f) Budget: Investigators must provide confirmation from their institution that the proposed budget is CIHR eligible. ACT funding must be used by June 30, 2026.
g) Acknowledgement: Applicants will acknowledge ACT Consortium partnership and funding in all related presentations and publications.
h) Progress Report: If funded, applicants must be accountable for their progress, which will be summarized in annual ACT reports. A summary of their project will also be shared within ACT to raise awareness and foster new collaborations.
i) Open-Access: Applicants commit to making their trial results publicly available (open-access publication).

PDF is missing key information.

Please revise PDF or application may be considered ineligible.

If there is a reason this has been excluded, please provide details here.

Expand

Yes

10. Submission PDF:

Please submit a single PDF with file name that includes the NPI last name and project acronym (e.g., "Smith_ProjectAcronym.pdf").
Letters of support should not be included in the application.
It is your responsibility to ensure the PDF contains all required components

PDF File

Select single file to upload

"Smith_ProjectAcronym.pdf"

Please submit application using the [SUBMIT] button at the bottom of the form.

You have selected an option that triggers this survey to end right now.

To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.